Parasitic infections in HIV infected individuals: Diagnostic & therapeutic challenges

Indian Journal of Medical Research

Volumn 134, Issue 12, 2011, Pages 878-897

  Nissapatorn, Veeranoot ^a   Sawangjaroen, Nongyao ^b  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b PRINCE OF SONGKLA UNIVERSITY   (Thailand)

Author keywords

AIDS; Anti parasitic treatment; Diagnosis; HAART; HIV infected individuals; IRIS; Parasitic opportunistic infections

Indexed keywords

ALBENDAZOLE; AMPHOTERICIN B LIPID COMPLEX; ATOVAQUONE; BENZNIDAZOLE; COTRIMOXAZOLE; DILOXANIDE FUROATE; FOLIC ACID ANTAGONIST; FOLINIC ACID; FURAZOLIDONE; IVERMECTIN; MEGLUMINE ANTIMONATE; METRONIDAZOLE; MILTEFOSINE; NIFURTIMOX; NITAZOXANIDE; ORNIDAZOLE; OXAMNIQUINE; PRAZIQUANTEL; PYRIMETHAMINE SULFADIAZINE; STIBOGLUCONATE SODIUM; TINIDAZOLE;

AFRICAN TRYPANOSOMIASIS; AMEBIASIS; ANOREXIA; BRAIN BIOPSY; CENTRAL NERVOUS SYSTEM INFECTION; CHAGAS DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CRYPTOSPORIDIOSIS; CRYPTOSPORIDIUM PARVUM; CYCLOSPORA; CYSTICERCUS CELLULOSAE; DIARRHEA; DRUG EFFICACY; ENTAMOEBA HISTOLYTICA; FECES ANALYSIS; GIARDIA LAMBLIA; GIARDIASIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; ISOSPORA BELLI; LEISHMANIA DONOVANI; LEISHMANIASIS; MALAISE; MALARIA; MICROSPORIDIA; NAUSEA; NEUROCYSTICERCOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PARASITE EXAMINATION; PLASMODIUM FALCIPARUM; REVIEW; SCHISTOSOMA HEMATOBIUM; SCHISTOSOMA JAPONICUM; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS; SEROLOGY; SKIN TEST; STRONGYLOIDES STERCORALIS; STRONGYLOIDIASIS; TAENIA SOLIUM; TASTE DISORDER; TERATOGENICITY; TOXOPLASMA GONDII; TOXOPLASMOSIS; TREATMENT FAILURE; TRYPANOSOMA CRUZI; VOMITING;

EID: 84856575687     PISSN: 09715916     EISSN: None     Source Type: Journal    
DOI: 10.4103/0971-5916.92633     Document Type: Review

References (175)

1. UNAIDS report on the global AIDS epidemic 2010 [homepage on the Internet]. Epidemic update. Available from: http://www. unaids.org/documents/20101123_GlobalReport_Chap2_em.pdf, accessed on August 25, 2011.
2. CDC. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR Surveill Summ 1987; 36: 1-15.
3. Akinbo FO, Okaka CE, Omoregie R. Prevalence of intestinal parasitic infections among HIV patients in B enin City, Nigeria. Libyan J Med 2010; 5-doi: 10.3402/ljm.v5i0.5506.
4. Mohandas, Sehgal R, Sud A, Malla N. Prevalence of intestinal parasitic pathogens in HIV-seropositive individuals in Northern India. Jpn J Infect Dis 2002; 55: 83-4.
5. Fontanet AL, Sahlu T, Rinke de Wit T, Messele T, Masho W, Woldemichael T, et al. Epidemiology of infections with intestinal parasites and human immunodeficiency virus (HIV) among sugar-estate residents in Ethiopia. Ann Trop Med Parasitol 2000; 94: 269-78.
6. Lindo JF, Dubon JM, Ager AL, de Gourville EM, Solo-Gabriele H, Klaskala WI, et al. Intestinal parasitic infections in human immunodeficiency virus (HIV)-positive and HIVnegative individuals in San Pedro Sula, Honduras. Am J Trop Med Hyg 1998; 58: 431-5.
7. Omalu ICJ, Yako AB, Duhlinska DD, Anyanwu GI, Pam VA, Inyama PU. First detection of intestinal microsporidia in Nigeria. Online J Health All Sci 2005; 3: 4.
8. Kulkarni SV, Kairon R, Sane SS, Padmawar PS, Kale VA, Thakar MR, et al. Opportunistic parasitic infections in HIV/AIDS patients presenting with diarrhoea by the level of immunesuppression. Indian J Med Res 2009; 131: 63-6.
9. Asma I, Johari S, Sim B HL, Lim YAL. How common is intestinal parasitism in HIV-infected patients in Malaysia? Trop Biomed 2011; 28: 400-10.
10. Siddiqui U, B ini EJ, Chandarana K, Leong J, Ramsetty S, Schiliro D, et al. Pravalence and impact of diarrhea on healthrelated quality of life in HIV-infected patients in the era of highly active antiretroviral therapy. J Clin Gastroenterol 2007; 41: 484-90.
11. Lagrange-Xélot M, Porcher R, Sarfati C, de Castro N, Carel O, Magnier JD, et al. Isosporiasis in patients with HIV infection in the highly active antiretroviral therapy era in France. HIV Med 2008; 9: 126-30.
12. Chhin S, Harwell JI, B ell JD, Rozycki G, Ellman T, B arnett JM, et al. Etiology of chronic diarrhea in antiretroviral-naive patients with HIV infection admitted to Norodom Sihanouk Hospital, Phnom Penh, Cambodia. Clin Infect Dis 2006; 43: 925-32.
13. Kosek M, Alcantara C, Lima AA, Guerrant RL. Cryptosporidiosis: an update. Lancet Infect Dis 2001; 1: 262-9.
14. Wiwanitkit V. Intestinal parasitic infections in Thai HIVinfected patients with different immunity status. BMC Gastroenterol 2001; 1: 3.
15. Leelayoova S, Vithayasai N, Watanaveeradej V, Chotpitayasunondh T, Therapong V, Naaglor T, et al. Intestinal microsporidiosis in HIV-infected children with acute and chronic diarrhea. Southeast Asian J Trop Med Public Health 2001; 32: 33-7.
16. Wanachiwanawin D, Chokephaibulkit K, Lertlaituan P, Ongrotchanakun J, Chinabut P, Thakerngpol K. Intestinal microsporidiosis in HIV-infected children with diarrhea. Southeast Asian J Trop Med Public Health 2002; 33: 241-5.
17. Sokolova OI, Demyanov AV, B owers LC, Didier ES, Yakovlev AV, Skarlato SO, et al. Emerging microsporidian infections in Russian HIV-infected patients. J Clin Microbiol 2011; 49: 2102-8.
18. Didier ES, Weiss LM. Microsporidiosis: not just in AIDS patients. Curr Opin Infect Dis 2011; 24: 490-5.
19. Stauffer W, Radvin JI. Entamoeba histolytica: an update. Curr Opin Infect Dis 2003; 16: 479-85.
20. Haque R, Huston CD, Hughes M, Houpt E, Petri WA. Amebiasis. N Engl J Med 2003; 348: 1565-73.
21. Hung CC, Wu PY, Chang SY, Ji DD, Sun HY, Liu WC, et al. Amebiasis among persons who sought voluntary counseling and testing for human immunodeficiency virus infection: a case-control study. Am J Trop Med Hyg 2011; 84: 65-9.
22. Chen Y, Zhang Y, Yang B, Qi T, Lu H, Cheng X, et al. Seroprevalence of Entamoeba histolytica infection in HIVInfected patients in China. Am J Trop Med Hyg 2007; 77: 825-8.
23. Hung CC, Wu PY, Chang SY, Ji DD, Sun HY, Liu WC, et al. Amebiasis among persons who sought voluntary counseling and testing for human immunodeficiency virus infection: a case control study. Am J Trop Med Hyg 2011; 84: 65-9.
24. Lee YJ, Chen KJ, Yang CH, Lin YC, Liu HY, Liao ST, et al. Characteristics of amebic liver abscess in patients with or without human immunodeficiency virus. J Microbiol Immunol Infect 2009; 42: 500-4.
25. Wu KS, Tsai HC, Lee SS, Liu YC, Wann SR, Wang YH, et al. Comparison of clinical characteristics of amebic liver abscess in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients. J Microbiol Immunol Infect 2008; 41: 456-61.
26. Feitosa G, B andeira AC, Sampaio DP, B adaró R, B rites C. High prevalence of giardiasis and stronglyloidiasis among HIV-infected patients in B ahia, B razil. Braz J Infect Dis 2001; 5: 339-44.
27. Chui DW, Owen RL. AIDS and the gut. J Gastroenterol Hepatol 1994; 9: 291-303.
28. Hailemariam G, Kassu A, Abebe G, Abate E, Damte D, Mekonnen E, et al. Intestinal parasitic infections in HIV/AIDS and HIV seronegative individuals in a teaching hospital, Ethiopia. Jpn J Infect Dis 2004; 57: 41-3.
29. Angarano G, Maggi P, Di B ari MA, Larocca AM, Congedo P, Di B ari C, et al. Giardiasis in HIV: A possible role in patients with severe immune deficiency. Eur J Epidemiol 1997; 13: 485-7.
30. Phillips MA, Stanley Jr SL. Chemotherapy of protozoal infections: Amebiasis, giardiasis, trichomoniasis, trypanosomiasis, leishmaniasis, and other protozoal infections. In: B runton LL, Chabner B A, Knollmann B C, editors. Goodman & Gilman's the pharmacological basis of therapeutics, 12th ed. New York: McGraw-Hill; 2001.
31. Fujishima T, Nishise S, Ichihara M, Kobayashi S, Takeuchi T. Difficulties in the treatment of intestinal amoebiasis in mentally disabled individuals at a rehabilitation institution for the intellectually impaired in Japan. Chemotherapy 2010; 56: 348-52.
32. Wiwanitkit V, Srisupanant M. Cryptosporidiosis occurrence in anti-HIV-seropositive patients attending a sexually transmitted diseases clinic, Thailand. Trop Doct 2006; 36: 64.
33. WHO. Control of the leishmaniases. WHO Technical Report Series 2010; 949: 1-104.
34. Alvar J, B ashaye S, Argaw D, Cruz I, Aparicio P, Kassa A, et al. Kala-azar outbreak in Libo Kemkem, Ethiopia: epidemiologic and parasitologic assessment. Am J Trop Med Hyg 2007; 77: 275-82.
35. Alvar J, Aparicio P, Aseffa A, Den B oer M, Cañavate C, Dedet JP, et al. The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev 2008; 21: 334-59.
36. Reithinger R, Dujardin JC, Louzir H, Pirmez C, Alexander B, Brooker S. Cutaneous leishmaniasis. Lancet Infect Dis 2007; 7: 581-96.
37. Paredes R, Munoz J, Diaz I, Domingo P, Gurgui M, Clotet B. Leishmaniasis in HIV infection. J Postgrad Med 2003; 49: 39-49.
38. Guiguemdé RT, Sawadogo OS, B ories C, Traore KL, Nezien D, Nikiema L, et al. Leishmania major and HIV co-infection in Burkina Faso. Trans R Soc Trop Med Hyg 2003; 97: 168-9.
39. Rabello A, Orsini M, Disch J. Leishmania/HIV co-infection in Brazil: an appraisal. Ann Trop Med Parasitol 2003; 97 (Suppl 1)17-28.
40. Chakravarty J, Kumar S, Kumar R, Gautam S, Rai M, Sundar S. Evaluation of rk39 immunochromatographic test with urine for diagnosis of visceral leishmaniasis. Trans R Soc Trop Med Hyg 2011; 105: 537-9.
41. Desjeux P. Global control and Leishmania HIV co-infection. Clin Dermatol 1999; 17: 317-25.
42. Calza L, D'Antuono A, Marinacci G, Manfredi R, Colangeli V, Passarini B, et al. Disseminated cutaneous leishmaniasis after visceral disease in a patient with AIDS. J Am Acad Dermatol 2004; 50: 461-5.
43. Schönian G, Nasereddin A, Dinse N, Schweynoch C, Schallig HD, Presber W, et al. PCR diagnosis and characterization of Leishmania in local and imported clinical samples. Diagn Microbiol Infect Dis 2003; 47: 349-58.
44. Antinori S, Longhi E, B estetti G, Piolini R, Acquaviva V, Foschi A, et al. Post-kala-azar dermal leishmaniasis as an immune reconstitution inflammatory syndrome in a patient with acquired immune deficiency syndrome. Br J Dermatol 2007; 157: 1032-6.
45. Ritmeijer K, Veeken H, Melaku Y, Leal G, Amsalu R, Seaman J, et al. Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV coinfected patients have a poor outcome. Trans R Soc Trop Med Hyg 2001; 95: 668-72.
46. Rosenthal E, Marty P. Recent understanding in the treatment of visceral leishmaniasis. J Postgrad Med 2003; 49: 61-8.
47. Davidson RN, Russo R. Relapse of visceral leishmaniasis in patients who were coinfected with human immunodeficiency virus and who received treatment with liposomal amphotericin B. Clin Infect Dis 1994; 19: 560.
48. WHO 2009. Reported malaria cases and deaths [cited 2011 Aug 25] Available from: http://www.who.int/malaria/world_malaria_report_2010/wmr2010_annex7a.pdf, accessed on August 25, 2011.
49. Idemyor V. Human immunodeficiency virus (HIV) and malaria interaction in sub-Saharan Africa: the collision of two Titans. HIV Clin Trials 2007; 8: 246-53.
50. Cruciani M, Nardi S, Malena M, B osco O, Serpelloni G, Mengoli C. Systematic review of the accuracy of the ParaSight-F test in the diagnosis of Plasmodium falciparum malaria. Med Sci Monit 2004; 10: MT81-8.
51. Patankar TF, Karnad DR, Shetty PG, Desai AP, Prasad SR. Adult cerebral malaria: prognostic importance of imaging findings and correlation with postmortem findings. Radiology 2002; 224: 811-6.
52. Cordoliani YS, Sarrazin JL, Felten D, Caumes E, Lévêque C, Fisch A. MR of cerebral malaria. AJNR Am J Neuroradiol 1998; 19: 871-4.
53. Mohsen AH, McKendrick MW, Schmid ML, Green ST, Hadjivassiliou M, Romanowski C. Postmalaria neurological syndrome: a case of acute disseminated encephalomyelitis? J Neurol Neurosurg Psychiatry 2000; 68: 388-9.
54. WHO. 2008. Essential prevention and care interventions for adults and adolescents living with HIV in resource-limited settings. Available from: http://www.who.int/hiv/pub/prev_care/OMS_EPP_AFF_en.pdf, accessed on December 6, 2011.
55. Garcia HH, Pretell J, Gilman RH; Cysticercosis Working Group in Peru. Neurocysticercosis and the global world. J Neurol 2002; 249: 1107-8.
56. Garcia HH, Del B rutto OH; Cysticercosis Working Group in Peru. Neurocysticercosis: updated concepts about an old disease. Lancet Neurol 2005; 4: 653-61.
57. Walker M, Zunt JR. Parasitic central nervous system infections in immunocompromised hosts. Clin Infect Dis 2005; 40: 1005-15.
58. Takayanagui OM, Odashima NS, B onato PS, Lima JE, Lanchote VL. Medical management of neurocysticercosis. Expert Opin Pharmacother 2011; 12: 2845-56.
59. WHO Expert Committee. Prevention and control of schistosomiasis and soil-transmitted helminthiasis. World Health Organ Tech Rep Ser 2002; 912: i-vi, 1-57.
60. Ross AG, B artley PB, Sleigh AC, Olds GR, Li Y, Williams GM, et al. Schistosomiasis. N Engl J Med 2002; 346: 1212-20.
61. Smith C, Smith H, Seaton RA, Fox R. Seroprevalence of schistosomiasis in African patients infected with HIV. HIV Med 2008; 9: 436-9.
62. de Avila RE, B atista TS, Xavier MA, Nogueira AM, Lambertucci JR. Schistosomiasis mansoni and severe gastrointestinal cytomegalovirus disease in a patient with acquired immunodeficiency syndrome. Rev Soc Bras Med Trop 2006; 39: 379-82.
63. Carod-Artal FJ. Neuroschistosomiasis. Expert Rev Anti Infect Ther 2010; 8: 1307-18.
64. Carod-Artal FJ. Neurological complications of Schistosoma infection. Trans R Soc Trop Med Hyg 2008; 102: 107-16.
65. Ferrari TC. Involvement of central nervous system in the schistosomiasis. Mem Inst Oswaldo Cruz 2004; 99 (5 Suppl 1): 59-62.
66. Zhu YC. Immunodiagnosis and its role in schistosomiasis control in China: a review. Acta Trop 2005; 96: 130-6.
67. Van Gool T, Vetter H, Vervoort T, Doenhoff MJ, Wetsteyn J, Overbosch D. Serodiagnosis of imported schistosomiasis by a combination of a commercial indirect hemagglutination test with Schistosoma mansoni adult worm antigens and an enzyme-linked immunosorbent assay with S. mansoni egg antigens. J Clin Microbiol 2002; 40: 3432-7.
68. Fowler R, Lee C, Keystone JS. The role of corticosteroids in the treatment of cerebral schistosomiasis caused by Schistosoma mansoni: case report and discussion. Am J Trop Med Hyg 1999; 61: 47-50.
69. Liu HQ, Feng XY, Yao ZW, Sun HP. Characteristic magnetic resonance enhancement pattern in cerebral schistosomiasis. Chin Med Sci J 2006; 21: 223-7.
70. Ferrari ML, Coelho PM, Antunes CM, Tavares CA, da Cunha AS. Efficacy of oxamniquine and praziquantel in the treatment of Schistosoma mansoni infection: a controlled trial. Bull World Health Organ 2003; 81: 190-6.
71. Xiao SH, You JQ, Gao HF, Mei JY, Jiao PY, Chollet J, et al. Schistosoma japonicum: effect of artemether on glutathione S-transferase and superoxide dismutase. Exp Parasitol 2002; 102: 38-45.
72. Karanja DM, Hightower AW, Colley DG, Mwinzi PN, Galil K, Andove J, et al. Resistance to reinfection with Schistosoma mansoni in occupationally exposed adults and effect of HIV-1 co-infection on susceptibility to schistosomiasis: a longitudinal study. Lancet 2002; 360: 592-6.
73. Rivero FD, Kremer LE, Allende L, Casero RD. Strongyloides stercoralis and HIV: a case report of an indigenous disseminated infection from non-endemic area. Rev Argent Microbiol 2006; 38: 137-9.
74. Viney ME, B rown M, Omoding NE, B ailey JW, Gardner MP, Roberts E, et al. Why does HIV infection not lead to disseminated strongyloidiasis? J Infect Dis 2004; 190: 2175-80.
75. Keiser PB, Nutman TB. Strongyloides stercoralis in the Immunocompromised Population. Clin Microbiol Rev 2004; 17: 208-17.
76. Walker MD, Zunt JR. Neuroparasitic infections: nematodes. Semin Neurol 2005; 25: 252-61.
77. Siddiqui AA, B erk SL. Diagnosis of Strongyloides stercoralis infection. Clin Infect Dis 2001; 33: 1040-7.
78. Nissapatorn V, Lee C, Quek KF, Leong CL, Mahmud R, Abdullah KA. Toxoplasmosis in HIV/AIDS patients: a current situation. Jpn J Infect Dis 2004; 57: 160-5.
79. Israeski DM, Remington JS. AIDS-associated toxoplasmosis. In: Sande MA, Volberding PA, editors. The medical management of AIDS. Philadelphia, WB Saunders; 1992. p. 319-45.
80. Carme B, M'Pele P, Mbitsi A, Kissila AM, Aya GM, Mouanga-Yidika G, et al. Opportunistic parasitic diseases and mycoses in AIDS. Their frequencies in B razzaville (Congo). Bull Soc Pathol Exot Filiales 1988; 81: 311-6.
81. Colombo FA, Vidal JE, Penalva de Oliveira AC, Hernandez AV, B onasser-Filho F, Nogueira RS, et al. Diagnosis of cerebral toxoplasmosis in AIDS patients in B razil: importance of molecular and immunological methods using peripheral blood samples. J Clin Microbiol 2005; 43: 5044-7.
82. Vidal JE, Hernandez AV, de Oliveira AC, Dauar RF, B arbosa SP Jr, Focaccia R. Cerebral toxoplasmosis in HIV-positive patients in B razil: clinical features and predictors of treatment response in the HAART era. AIDS Patient Care STDS 2005; 19: 626-34.
83. Pereira-Chioccola VL, Vidal JE, Su C. Toxoplasma gondii infection and cerebral toxoplasmosis in HIV-infected patients. Future Microbiol 2009; 4: 1363-79.
84. Luft B J. Toxoplasma gondii. In: Walzer PD, Gertz R, editors. Parasitic infection in the compromised host. New York: Marcel Dekker; 1989. p. 179-279.
85. Luft B J, Remington JS. Toxoplasmic encephalitis in AIDS. Clin Infect Dis 1992; 15: 211-22.
86. Reischl U, B retagne S, Krüger D, Ernault P, Costa JM. Comparison of two DNA targets for the diagnosis of Toxoplasmosis by real-time PCR using fluorescence resonance energy transfer hybridization probes. BMC Infect Dis 2003; 3: 7.
87. Antinori A. Evaluation and management of intracranial mass lesions in AIDS: Report of the Quality Standard Subcommittee of the American Academy of Neurology. Neurology 1998; 51: 1233-4.
88. Yeo KK, Yeo TT, Chan CY, Sitoh YY, Teo J, Wong SY. Stereotactic brain biopsies in AIDS patients-early local experience. Singapore Med J 2000; 41: 161-6.
89. Sadler M, B rink NS, Gazzard B G. Management of intracerebral lesions in patients with HIV: a retrospective study with discussion of diagnostic problems. QJM 1998; 91: 205-17.
90. Armbruster C, Alesch F, B udka H, Kriwanek S. Stereotactic brain biopsy in AIDS patients: a necessary patient-oriented and cost-effective diagnostic measure?. Acta Med Austriaca 1998; 25: 91-5.
91. Cota GF, Assad EC, Christo PP, Giannetti AV, Santos Filho JA, Xavier MA. Ventriculitis: a rare case of primary cerebral toxoplasmosis in AIDS patient and literature review. Braz J Infect Dis 2008; 12: 101-4.
92. Portegies P, Solod L, Cinque P, Chaudhuri A, B egovac J, Everall I, et al. Guidelines for the diagnosis and management of neurological complications of HIV infection. Eur J Neurol 2004; 11: 297-304.
93. Kung DH, Hubenthal EA, Kwan JY, Shelburne SA, Goodman JC, Kass JS. Toxoplasmosis myelopathy and myopathy in an AIDS patient: a case of immune reconstitution inflammatory syndrome? Neurologist 2011; 17: 49-51.
94. Chirgwin K, Hafner R, Leport C, Remington J, Andersen J, Bosler EM, et al. Randomized phase II trial of atovaquone with pyrimethamine or sulfadiazine for treatment of toxoplasmic encephalitis in patients with acquired immunodeficiency syndrome: ACTG 237/ANRS 039 Study. AIDS Clinical Trials Group 237/Agence Nationale de Recherche sur le SIDA, Essai 039. Clin Infect Dis 2002; 34: 1243-50.
95. Baggish AL, Hill DR. Antiparasitic agent atovaquone. Antimicrob Agents Chemother 2002; 46: 1163-73.
96. Coura JR. Chagas disease: what is known and what is needed--a background article. Mem Inst Oswaldo Cruz 2007; 102 (Suppl 1): 113-22.
97. Jackson Y, Myers C, Diana A, Marti HP, Wolff H, Chappuis F, et al. Congenital transmission of Chagas disease in Latin American immigrants in Switzerland. Emerg Infect Dis 2009; 15: 601-3.
98. Vaidian AK, Weiss LM, Tanowitz HB. Chagas' disease and AIDS. Kinetoplastid Biol Dis 2004; 3: 2.
99. Antunes AC, Cecchini FM, B olli FB, Oliveira PP, Reboucas RG, Monte TL, et al. Cerebral trypanosomiasis and AIDS. Arq Neuropsiquiatr 2002; 60: 730-3.
100. Sica RE, Gargiullo G, Papayanis C. Tumour-like chagasic encephalitis in AIDS patients: an atypical presentation in one of them and outcome in a small series of cases. Arq Neuropsiquiatr 2008; 66: 881-4.
101. Madalosso G, Pellini AC, Vasconcelos MJ, Ribeiro AF, Weissmann L, Oliveira Filho GS, et al. Chagasic meningoencephalitis: case report of a recently included AIDSdefining illness in B razil. Rev Inst Med Trop Sao Paulo 2004; 46: 199-202.
102. Cordova E, B oschi A, Ambrosioni J, Cudos C, Corti M. Reactivation of Chagas disease with central nervous system involvement in HIV-infected patients in Argentina, 1992-2007. Int J Infect Dis 2008; 12: 587-92.
103. Ferreira MS, B orges AS. Some aspects of protozoan infections in immunocompromised patients-a review. Mem Inst Oswaldo Cruz 2002; 97: 443-57.
104. DiazGranados CA, Saavedra-Trujillo CH, Mantilla M, Valderrama SL, Alquichire C, Franco-Paredes C. Chagasic encephalitis in HIV patients: common presentation of an evolving epidemiological and clinical association. Lancet Infect Dis 2009; 9: 324-30.
105. Burgos JM, B egher SB, Freitas JM, B isio M, Duffy T, Altcheh J, et al. Molecular diagnosis and typing of Trypanosoma cruzi populations and lineages in cerebral Chagas disease in a patient with AIDS. Am J Trop Med Hyg 2005; 73: 1016-8.
106. Pittella JE. Central nervous system involvement in Chagas disease: a hundred-year-old history. Trans R Soc Trop Med Hyg 2009; 103: 973-8.
107. Montero A, Cohen JE, Martínez DP, Giovannoni AG. Empirical anti-toxoplasma therapy in cerebral AIDS and Chagas disease. Presentation of 2 cases, review of the literature and proposal of an algorithm. Medicina (B Aires) 1998; 58: 504-6.
108. Corti M. AIDS and Chagas' disease. AIDS Patient Care STDS 2000; 14: 581-8.
109. Barratt JL, Harkness J, Marriott D, Ellis JT, Stark D. Importance of nonenteric protozoan infections in immunocompromised people. Clin Microbiol Rev 2010; 23: 795-836.
110. Maldonado C, Albano S, Vettorazzi L, Salomone O, Zlocowski JC, Abiega C, et al. Using polymerase chain reaction in early diagnosis of re-activated Trypanosoma cruzi infection after heart transplantation. J Heart Lung Transplant 2004; 23: 1345-8.
111. Diez M, Favaloro L, B ertolotti A, B urgos JM, Vigliano C, Lastra MP, et al. Usefulness of PCR strategies for early diagnosis of Chagas' disease reactivation and treatment follow-up in heart transplantation. Am J Transplant 2007; 7: 1633-40.
112. Piron M, Fisa R, Casamitjana N, López-Chejade P, Puig L, Vergés M, et al. Development of a real-time PCR assay for Trypanosoma cruzi detection in blood samples. Acta Trop 2007; 103: 195-200.
113. Corti M, Yampolsky C. Prolonged survival and immune reconstitution after chagasic meningoencephalitis in a patient with acquired immunodeficiency syndrome. Rev Soc Bras Med Trop 2006; 39: 85-8.
114. Sartori AM, Caiaffa-Filho HH, B ezerra RC, do S Guilherme C, Lopes MH, Shikanai-Yasuda MA. Exacerbation of HIV viral load simultaneous with asymptomatic reactivation of chronic Chagas' disease. Am J Trop Med Hyg 2002; 67: 521-3.
115. Kennedy PG. The continuing problem of human African trypanosomiasis (sleeping sickness). Ann Neurol 2008; 64: 116-26.
116. Barat C, Pepin J, Tremblay MJ. HIV-1 replication in monocytederived dendritic cells is stimulated by melarsoprol, one of the main drugs against human African trypanosomiasis. J Mol Biol 2011; 410: 1052-64.
117. CDC. Laboratory diagnosis of parasites of public health concern. Atlanta, GA: CDC, 2003.
118. Lejon V, B oelaert M, Jannin J, Moore A, B üscher P. The challenge of Trypanosoma brucei gambiense sleeping sickness diagnosis outside Africa. Lancet Infect Dis 2003; 3: 804-8.
119. Lejon V, B uscher P. Stage determination and follow-up in sleeping sickness. Med Trop (Mars) 2001; 61: 355-60.
120. Kennedy PG. Human African trypanosomiasis of the CNS: current issues and challenges. J Clin Invest 2004; 113: 496-504.
121. Gill DS, Chatha DS, del Carpio-O'Donovan R. MR imaging findings in African trypansomiasis. AJNR Am J Neuroradiol 2003; 24: 1383-5.
122. Matovu E, Seebeck T, Enyaru JC, Kaminsky R. Drug resistance in Trypanosoma brucei spp., the causative agents of sleeping sickness in man and nagana in cattle. Microbes Infect 2001; 3: 763-70.
123. Docampo R, Moreno SN. Current chemotherapy of human African trypanosomiasis. Parasitol Res 2003; 90 (Supp 1): S10-3.
124. Bouteille B, Oukem O, B isser S, Dumas M. Treatment perspectives for human African trypanosomiasis. Fundam Clin Pharmacol 2003; 17: 171-81.
125. Nok AJ. Arsenicals (melarsoprol), pentamidine and suramin in the treatment of human African trypanosomiasis. Parasitol Res 2003; 90: 71-9.
126. Blum J, Nkunku S, B urri C. Clinical description of encephalopathic syndromes and risk factors for their occurrence and outcome during melarsopol treatment of human African trypanosomiasis. Trop Med Int Health 2001; 6: 390-400.
127. de La Rosa R, Pineda JA, Delgado J, Macías J, Morillas F, Mira JA, et al. Incidence of and risk factors for symptomatic visceral leishmaniasis among human immunodeficiency virus type 1-infected patients from Spain in the era of highly active antiretroviral therapy. J Clin Microbiol 2002; 40: 762-7.
128. Lian YL, Heng B S, Nissapatorn V, Lee C. AIDSdefining illnesses: a comparison between before and after commencement of highly active antiretroviral therapy (HAART). Curr HIV Res 2007; 5: 484-9.
129. Silva MT, Araújo A. Highly active antiretroviral therapy access and neurological complications of human immunodeficiency virus infection: impact versus resources in B razil. J Neurovirol 2005; 11 (Suppl 3): 11-5.
130. Tsambiras PE, Larkin JA, Houston SH. Case report. Toxoplasma encephalitis after initiation of HAART. AIDS Read 2001; 11: 608-10.
131. de B oer J, Wulffraat N, Rothova A. Visual loss in uveitis of childhood. Br J Ophthalmol 2003; 87: 879-84.
132. Sendi P, Sachers F, Drechsler H, Graber P. Immune recovery vitritis in an HIV patient with isolated toxoplasmic retinochoroiditis. AIDS 2006; 20: 2237-8.
133. Chen KC, Chen JY, Tung GA. Case 149: Immune reconstitution inflammatory syndrome. Radiology 2009; 252: 924-8.
134. Caby F, Lemercier D, Coulomb A, Grigorescu R, Paris L, Touafek F, et al. Fetal death as a result of placental immune reconstitution inflammatory syndrome. J Infect 2010; 61: 185-8.
135. Belanger F, Derouin F, Grangeot-Keros L, Meyer L. Incidence and risk factors of toxoplasmosis in a cohort of human immunodeficiency virus-infected patients: 1988-1995. HEMOCO and SEROCO Study Groups. Clin Infect Dis 1999; 28: 575-81.
136. Ullum H, Victor J, Katzenstein TL, Gerstoft J, Gøtzsche PC, B endtzen K, et al. Decreased short-term production of tumor necrosis factor-alpha and interleukin-1beta in human immunodeficiency virus-seropositive subjects. J Infect Dis 1997; 175: 1507-10.
137. Jevtović DJ, Salemović D, Ranin J, Pesić I, Zerjav S, Djurković-Djaković O. The prevalence and risk of immune restoration disease in HIV-infected patients treated with highly active antiretroviral therapy. HIV Med 2005; 6: 140-3.
138. Furco A, Carmagnat M, Chevret S, Garin YJ, Pavie J, De Castro N, et al. Restoration of Toxoplasma gondii-specific immune responses in patients with AIDS starting HAART. AIDS 2008; 22: 2087-96.
139. Fournier S, Rabian C, Alberti C, Carmagnat MV, Garin JF, Charron D, et al. Immune recovery under highly active antiretroviral therapy is associated with restoration of lymphocyte proliferation and interferon-gamma production in the presence of Toxoplasma gondii antigens. J Infect Dis 2001; 183: 1586-91.
140. Venkataramana A, Pardo CA, McArthur JC, Kerr DA, Irani DN, Griffin JW, et al. Immune reconstitution inflammatory syndrome in the CNS of HIV-infected patients. Neurology 2006; 67: 383-8.
141. Tremont-Lukats IW, Garciarena P, Juarbe R, El-Abassi RN. The immune inflammatory reconstitution syndrome and central nervous system toxoplasmosis. Ann Intern Med 2009; 150: 656-7.
142. Desjeux P, Alvar J. Leishmania/HIV co-infections: epidemiology in Europe. Ann Trop Med Parasitol 2003; 97 (Suppl 1): 3-15.
143. Posada-Vergara MP, Lindoso JA, Tolezano JE, Pereira-Chioccola VL, Silva MV, Goto H. Tegumentary leishmaniasis as a manifestation of immune reconstitution inflammatory syndrome in 2 patients with AIDS. J Infect Dis 2005; 192: 1819-22.
144. Sinha S, Fernández G, Kapila R, Lambert WC, Schwartz RA. Diffuse cutaneous leishmaniasis associated with the immune reconstitution inflammatory syndrome. Int J Dermatol 2008; 47: 1263-70.
145. Chrusciak-Talhari A, Ribeiro-Rodrigues R, Talhari C, Silva RM Jr, Ferreira LC, B otileiro SF, et al. Tegumentary leishmaniasis as the cause of immune reconstitution inflammatory syndrome in a patient co-infected with human immunodeficiency virus and Leishmania guyanensis. Am J Trop Med Hyg 2009; 81: 559-64.
146. Neva FA. B iology and immunology of human strongyloidiasis. J Infect Dis 1986; 153: 397-406.
147. Ridolfo AL, Gervasoni C, Antinori S, Pizzuto M, Santambrogio S, Trabattoni D, et al. Post-kala-azar dermal leishmaniasis during highly active antiretroviral therapy in an AIDS patient infected with Leishmania infantum. J Infect 2000; 40: 199-202.
148. Gilad J, B orer A, Hallel-Halevy D, Riesenberg K, Alkan M, Schlaeffer F. Post-kala-azar dermal leishmaniasis manifesting after initiation of highly active anti-retroviral therapy in a patient with human immunodeficiency virus infection. Isr Med Assoc J 2001; 3: 451-2.
149. Belay AD, Asafa Y, Mesure J, Davidson RN. Successful miltefosine treatment of post-kala-azar dermal leishmaniasis occurring during antiretroviral therapy. Ann Trop Med Parasitol 2006; 100: 223-7.
150. Tadesse A, Hurissa Z. Leishmaniasis (PKDL) as a case of immune reconstitution inflammatory syndrome (IRIS) in HIV-positive patient after initiation of anti-retroviral therapy (ART). Ethiop Med J 2009; 47: 77-9.
151. Gelanew T, Amogne W, Abebe T, Kuhls K, Hailu A, Schönian G. A clinical isolate of Leishmania donovani with ITS1 sequence polymorphism as a cause of para-kala-azar dermal leishmaniasis in an Ethiopian human immunodeficiency virus-positive patient on highly active antiretroviral therapy. Br J Dermatol 2010; 163: 870-4.
152. Kim AC, Lupatkin HC. Strongyloides stercoralis infection as a manifestation of immune restoration syndrome. Clin Infect Dis 2004; 39: 439-40.
153. Lanzafame M, Faggian F, Lattuada E, Antolini D, Vento S. Strongyloidiasis in an HIV-1-infected patient after highly active antiretroviral therapy-induced immune restoration [letter]. J Infect Dis 2005; 191: 1027.
154. Brown M, Miiro G, Nkurunziza P, Watera C, Quigley MA, Dunne DW, et al. Schistosoma mansoni, nematode infections, and progression to active tuberculosis among HIV-1-infected Ugandans. Am J Trop Med Hyg 2006; 74: 819-25.
155. Taylor CL, Subbarao V, Gayed S, Ustianowski AP. Immune reconstitution syndrome to Strongyloides stercoralis infection. AIDS 2007; 21: 649-50.
156. Plasencia LD, Socas Mdel M, Valls RA, Fernández EM, Higuera AC, Gutierrez AB. Terminal ileitis as a manifestation of immune reconstitution syndrome following HAART. AIDS 2006; 20: 1903-5.
157. Shah I. Immune Reconstitution Syndrome in HIV-1 infected children-a study from India. Indian J Pediatr 2011; 78: 540-3.
158. Subsai K, Kanoksri S, Siwaporn C, Helen L, Kanokporn O, Wantana P. Neurological complications in AIDS patients receiving HAART: a 2-year retrospective study. Eur J Neurol 2006; 13: 233-9.
159. Auyeung P, French MA, Hollingsworth PN. Immune restoration disease associated with Leishmania donovani infection following antiretroviral therapy for HIV infection. J Microbiol Immunol Infect 2010; 43: 74-6.
160. Blanche P, Gombert B, Rivoal O, Abad S, Salmon D, B rezin A. Uveitis due to Leishmania major as part of HAARTinduced immune restitution syndrome in a patient with AIDS. Clin Infect Dis 2002; 34: 1279-80.
161. Berry A, Abraham B, Dereure J, Pinzani V, B astien P, Reynes J. Two case reports of symptomatic visceral leishmaniasis in AIDS patients concomitant with immune reconstitution due to antiretroviral therapy. Scand J Infect Dis 2004; 36: 225-7.
162. Kérob D, B ouaziz JD, Sarfati C, Pavie J, Vignon-Pennamen MD, Menotti J, et al. First case of cutaneous reconstitution inflammatory syndrome associated with HIV infection and leishmaniasis. Clin Infect Dis 2006; 43: 664-6.
163. Martin-Blondel G, Alvarez M, Delobel P, Uro-Coste E, Cuzin L, Cuvinciuc V, et al. Toxoplasmic encephalitis IRIS in HIVinfected patients: a case series and review of the literature. J Neurol Neurosurg Psychiatry 2011; 82: 691-3.
164. Rodriguez-Rosado R, Soriano V, Dona C, González-Lahoz J. Opportunistic infections shortly after beginning highly active antiretroviral therapy. Antivir Ther 1998; 3: 229-31.
165. Jiménez-Expósito MJ, Alonso-Villaverde C, Sardà P, Masana L. Visceral leishmaniasis in HIV-infected patients with nondetectable HIV-1 viral load after highly active antiretroviral therapy. AIDS 1999; 13: 152-3.
166. González-Castillo J, B lanco F, Soriano V, B arreiro P, Concepción B ravo M, Jiménez-Nácher I, et al. Opportunistic episodes in patients infected with the human immunodeficiency virus during the first 6 months of HAART. Med Clin (Barc) 2001; 117: 81-4.
167. Javid B, Aliyu SH, Save VE, Carmichael AJ, Lever AM. Schistosomal colonic polyposis in an HIV-positive man. AIDS 2007; 21: 386-8.
168. Fernando R, Miller R. Immune reconstitution eosinophilia due to schistosomiasis. Sex Transm Infect 2002; 78: 76.
169. de Silva S, Walsh J, B rown M. Symptomatic Schistosoma mansoni infection as an immune restoration phenomenon in a patient receiving antiretroviral therapy. Clin Infect Dis 2006; 42: 303-4.
170. McCombe JA, Auer RN, Maingat FG, Houston S, Gill MJ, Power C. Neurologic immune reconstitution inflammatory syndrome in HIV/AIDS: outcome and epidemiology. Neurology 2009; 72: 835-41.
171. Serpa JA, Moran A, Goodman JC, Giordano TP, White AC Jr. Neurocysticercosis in the HIV era: a case report and review of the literature. Am J Trop Med Hyg 2007; 77: 113-7.
172. Albrecht H. Leishmaniosis-new perspectives on an underappreciated opportunistic infection. AIDS 1998; 12: 2225-6.
173. Cabral RF, Valle B ahia PR, Gasparetto EL, Chimelli L. Immune reconstitution inflammatory syndrome and cerebral toxoplasmosis. AJNR Am J Neuroradiol 2010; 31: E65-6.
174. Huruy K, Mulu A, Mengistu G, Shewa-Amare A, Akalu A, Kassu A, et al. Immune reconstitution inflammatory syndrome among HIV/AIDS patients during highly active antiretroviral therapy in Addis Ababa, Ethiopia. Jpn J Infect Dis 2008; 61: 205-9.
175. Klotz SA, Aziz Mohammed A, Girmai Woldemichael M, Worku Mitku M, Handrich M. Immune reconstitution inflammatory syndrome in a resource-poor setting. J Int Assoc Physicians AIDS Care (Chic) 2009; 8: 122-7.